PFE - With Oral Anti-Obesity Candidate Development Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs | Benzinga
Thursday, Pfizer Inc (NYSE:PFE) announced it selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist.
Pfizer plans to conduct dose optimization studies in the second half of 2024, evaluating multiple doses of the preferred modified release formulation to inform the registration enabling studies.
In this PK study design, Goldman Sachs notes that it is unlikely to obtain significant tolerability data that could address the main criticisms of the company’s Phase 2b BID study. The earlier study had high rates of GI-related adverse events (mostly mild) and a high discontinuation rate, which disappointed both the firm and investors.
From an efficacy perspective, the Phase 2b BID study showed a weight loss of up to 11.7% at 32 weeks. This falls ...